Mariia S. Bogacheva

Dr. Mariia S. Bogacheva

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
XLXiaonan Liu
Xiaonan Liu
SHSini Huuskonen
Sini Huuskonen
TLTuomo Laitinen
Tuomo Laitinen
TRTaras Redchuk
Taras Redchuk
MBMariia S. Bogacheva
Mariia S. Bogacheva
MVMarkku Varjosalo
Markku Varjosalo
Treatment options for COVID‐19, caused by SARS‐CoV‐2, remain limited. Understanding viral pathogenesis at the molecular level is critical to develop effective therapy. Some recent studies have explored SARS‐CoV‐2–host interactomes and provided great resources for understanding viral replication. However, host proteins that functionally associate with SARS‐CoV‐2 are localized in the corresponding subnetwork within the comprehensive human interactome. Therefore, constructing a downstream network including all potential viral receptors, host cell proteases, and cofactors is necessary and should be used as an additional criterion for the validation of critical host machineries used for viral processing. This study applied both affinity purification mass spectrometry (AP‐MS) and the complementary proximity‐based labeling MS method (BioID‐MS) on 29 viral ORFs and 18 host proteins with potential roles in viral replication to map the interactions relevant to viral processing. The analysis yields a list of 693 hub proteins sharing interactions with both viral baits and host baits and revealed their biological significance for SARS‐CoV‐2. Those hub proteins then served as a rational resource for drug repurposing via a virtual screening approach. The overall process resulted in the suggested repurposing of 59 compounds for 15 protein targets. Furthermore, antiviral effects of some candidate drugs were observed in vitro validation using image‐based drug screen with infectious SARS‐CoV‐2. In addition, our results suggest that the antiviral activity of methotrexate could be associated with its inhibitory effect on specific protein–protein interactions.

1 October 2016 in Biomaterials
Verified
Journal Article
Open access
LKLiisa K. Kanninen
Liisa K. Kanninen
RHRiina Harjumäki
Riina Harjumäki
PPPasi Peltoniemi
Pasi Peltoniemi
MBMariia S. Bogacheva
Mariia S. Bogacheva
TSTuuli Salmi
Tuuli Salmi
Yan-Ru LouYan-Ru Lou
Yan-Ru Lou
Human pluripotent stem cells (hPSCs) have gained a solid foothold in basic research and drug industry as they can be used in vitro to study human development and have potential to offer limitless supply of various somatic cell types needed in drug development. Although the hepatic differentiation of hPSCs has been extensively studied, only a little attention has been paid to the role of the extracellular matrix. In this study we used laminin-511, laminin-521, and fibronectin, found in human liver progenitor cells, as culture matrices for hPSC-derived definitive endoderm cells. We observed that laminin-511 and laminin-521 either alone or in combination support the hepatic specification and that fibronectin is not a vital matrix protein for the hPSC-derived definitive endoderm cells. The expression of the laminin-511/521-specific integrins increased during the definitive endoderm induction and hepatic specification. The hepatic cells differentiated on laminin matrices showed the upregulation of liver-specific markers both at mRNA and protein levels, secreted human albumin, stored glycogen, and exhibited cytochrome P450 enzyme activity and inducibility. Altogether, we found that laminin-511 and laminin-521 can be used as stage-specific matrices to guide the hepatic specification of hPSC-derived definitive endoderm cells.

1 November 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MBMariia S. Bogacheva
Mariia S. Bogacheva
AEAnna Egorova
Anna Egorova
ASAnna Slita
Anna Slita
MMMarianna Maretina
Marianna Maretina
VBVladislav BARANOV
Vladislav BARANOV
Anton KiselevAnton Kiselev
Anton Kiselev

16 October 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MBMariia S. Bogacheva
Mariia S. Bogacheva
SKSofia Khan
Sofia Khan
LKLiisa K. Kanninen
Liisa K. Kanninen
MYMarjo Yliperttula
Marjo Yliperttula
ALAlan Leung
Alan Leung
Yan-Ru LouYan-Ru Lou
Yan-Ru Lou

23 January 2024 in Antiviral Research
Verified
Journal Article
Open access
MBMariia S. Bogacheva
Mariia S. Bogacheva
SKSuvi Kuivanen
Suvi Kuivanen
SPSwapnil Potdar
Swapnil Potdar
AHAntti Hassinen
Antti Hassinen
SHSini Huuskonen
Sini Huuskonen
OVOlli Vapalahti
Olli Vapalahti
The coronavirus disease 2019 (COVID-19) pandemic has heavily challenged the global healthcare system. Despite the vaccination programs, the new virus variants are circulating. Further research is required for understanding of the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and for discovery of therapeutic agents against the virus. Here, we took advantage of drug repurposing to identify if existing drugs could inhibit SARS-CoV-2 infection. We established an open high throughput platform for in vitro screening of drugs against SARS-CoV-2 infection. We screened ∼1000 drugs for their ability to inhibit SARS-CoV-2-induced cell death in the African green monkey kidney cell line (Vero-E6), analyzed how the hit compounds affect the viral N (nucleocapsid) protein expression in human cell lines using high-content microscopic imaging and analysis, determined the hit drug targets in silico, and assessed their ability to cause phospholipidosis, which can interfere with the viral replication. Duvelisib was found by in silico interaction assay as a potential drug targeting virus-host protein interactions. The predicted interaction between PARP1 and S protein, affected by Duvelisib, was further validated by immunoprecipitation. Our results represent a rapidly applicable platform for drug repurposing and evaluation of the new emerging viruses' responses to the drugs. Further in silico studies help us to discover the druggable host pathways involved in the infectious cycle of SARS-CoV-2.

7 June 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MBMariia S. Bogacheva
Mariia S. Bogacheva
MBMargarita A. Bystriakova
Margarita A. Bystriakova
Yan-Ru LouYan-Ru Lou
Yan-Ru Lou
Human induced pluripotent stem cells (hiPSCs) hold great potential as an unlimited source for obtaining hepatocyte-like cells (HLCs) for drug research. However, current applications of HLCs have been severely limited by the inability to produce mature hepatocytes from hiPSCs in vitro. Thyroid hormones are one of the hormones that surge during the perinatal period when liver maturation takes place. Here we assessed the influence of thyroid hormone on hepatic progenitor differentiation to HLCs. We analyzed gene and protein expression of early and late hepatic markers and demonstrated the selective activity of thyroid hormone on different genes. Particularly, we demonstrated thyroid hormone-dependent inhibition of the fetal hepatic marker AFP. Our study sheds light on the role of thyroid hormone during liver differentiation and maturation.